Welcome to our dedicated page for Outlook Therapeutics SEC filings (Ticker: OTLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outlook Therapeutics, Inc. (OTLK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Outlook Therapeutics is a biopharmaceutical company focused on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retina diseases such as wet AMD, and its filings give detailed insight into how this program is progressing through clinical, regulatory, and commercial stages.
Form 8-K current reports are particularly important for OTLK, as they document material events such as the resubmission of the Biologics License Application (BLA) for ONS-5010, FDA classification of the resubmission as a Class 1 review with an associated PDUFA goal date, and the completion of a Type A meeting to discuss a complete response letter (CRL). Other 8-K filings cover executive appointments and departures, stock option inducement grants, and the release of quarterly and annual financial results.
Investors can also use SEC filings to track Outlook Therapeutics’ listing details on The Nasdaq Stock Market LLC under the symbol OTLK, as well as to review risk factor discussions, financial condition, and updates on the NORSE clinical trial program and commercial launch activities referenced in periodic reports. These documents complement the company’s press releases by providing formal, structured descriptions of key events and agreements.
On Stock Titan, Outlook Therapeutics filings are updated as they are made available on EDGAR. AI-powered tools summarize lengthy disclosures, highlight the main points from forms such as 8-Ks and periodic reports, and make it easier to understand technical language around FDA interactions, clinical data references, and compensation arrangements. This allows readers to quickly grasp what each filing means for ONS-5010/LYTENAVA™, the company’s regulatory pathway, and its overall corporate developments.
Outlook Therapeutics reported a key regulatory update for ONS-5010 (bevacizumab-vikg). The U.S. Food and Drug Administration acknowledged receipt of the company’s resubmitted Biologics License Application and designated it a Class 1 review, which provides a two-month review period from the date of resubmission.
The FDA established a PDUFA goal date of December 31, 2025. This sets a clear timeline for the agency’s action on the resubmission and marks formal acceptance into the expedited review track associated with a Class 1 review.
Outlook Therapeutics filed an 8-K stating it has resubmitted the Biologics License Application for ONS-5010 to the U.S. Food and Drug Administration. The company also furnished a related press release as Exhibit 99.1 dated November 3, 2025.
The filing identifies the earliest event as November 3, 2025 and confirms the company’s Nasdaq listing under the symbol OTLK. The report was signed by Lawrence A. Kenyon, Chief Financial Officer.
Outlook Therapeutics, Inc. director Huang Andong received two stock option grants totaling 340,050 options: 286,734 options at an exercise price of $1.04 (granted 10/01/2025) and 53,316 options at $1.06 (granted 10/03/2025). The larger grant is an annual non-employee director award under the company's 2024 Equity Incentive Plan and fully vests on October 1, 2026 subject to continuous service.
The smaller grant was issued in lieu of $50,000 of cash fees and vests in four equal quarterly installments, finishing on September 30, 2026, subject to continuous service. Both option grants include acceleration upon a defined Change in Control if the reporting person remains in service immediately prior to that event.
Outlook Therapeutics director Julia A. Haller received two stock option grants reported on 10/01/2025 and 10/03/2025. The first grant is for 286,734 options with an exercise price of $1.04 that vest in full on 10/01/2026 subject to continued service and acceleration on a defined Change in Control. The second grant is for 58,648 options at $1.06, issued in lieu of $55,000 in cash fees and vesting in four equal quarterly installments through 9/30/2026, also subject to service and Change in Control acceleration.
Outlook Therapeutics director Kurt J. Hilzinger received two equity awards reported on 10/01/2025 and 10/03/2025. The filings show a stock option for 286,734 shares priced at $1.04 that vests in full on 10/01/2026 with acceleration on a Change in Control, and a stock option for 90,638 shares priced at $1.06 granted in lieu of $85,000 cash fees that vest in four equal quarterly installments ending 09/30/2026, also subject to Change in Control acceleration. Both option grants are held directly by the reporting person and have an expiration date of 10/01/2035 or 10/03/2035 respectively. The report was filed by one reporting person and signed by an attorney-in-fact on 10/03/2025.
Outlook Therapeutics director Julian S. Gangolli was granted a non‑employee director stock option on 10/01/2025 to buy 286,734 shares of common stock at an exercise price of $1.04 per share. The option is an annual grant under the company’s Non‑Employee Director Compensation Policy and the 2024 Equity Incentive Plan. The option shall fully vest on 10/01/2026 provided the director continues service through that date, and the underlying shares are subject to acceleration on a Change in Control if the director is in service immediately before such event. The filing was reported on Form 4 and signed by an attorney‑in‑fact on behalf of the reporting person.
Outlook Therapeutics, Inc. (OTLK) director Yezan Munther Haddadin reported two option grants. On 10/01/2025 he was granted 286,734 stock options with a $1.04 exercise price that, per the issuer, "shall fully vest on October 1, 2026" subject to continuous service and acceleration on a Change in Control. On 10/03/2025 he received 95,969 options with a $1.06 exercise price granted in lieu of $90,000 in cash fees; these vest in four equal quarterly installments and become fully vested on September 30, 2026, subject to continuous service and similar Change in Control acceleration. Both option grants expire in 2035 and are reported as direct beneficial ownership. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Outlook Therapeutics (OTLK) reported a director equity award on Form 4. The reporting person received a stock option for 286,734 shares at an exercise price of $1.04 on 10/01/2025. According to the disclosure, this annual grant under the 2024 Equity Incentive Plan vests in full on 10/01/2026, with potential acceleration upon a Change in Control.
A separate stock option for 58,648 shares at an exercise price of $1.06 was granted on 10/03/2025 in lieu of $55,000 of cash director fees. These options vest in four equal quarterly installments, fully vested by 09/30/2026, and are also subject to acceleration upon a Change in Control under the plan terms.
Outlook Therapeutics, Inc. (OTLK) reported stock option grants to director Faisal G. Sukhtian consisting of 286,734 options at an exercise price of $1.04 (grant date 10/01/2025) and 117,296 options at $1.06 (grant date 10/03/2025), for a total of 404,030 options. The first grant is an annual non-employee director award that fully vests on 10/01/2026 subject to continued service and accelerates upon a Change in Control. The second grant was issued in lieu of $110,000 in cash fees and vests in four equal quarterly installments, fully vesting on 09/30/2026, subject to continued service and Change in Control acceleration.
Outlook Therapeutics, Inc. reported that it has completed a requested Type A meeting with the U.S. Food and Drug Administration regarding the complete response letter dated August 27, 2025 for its biologics license application resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab for wet age-related macular degeneration. Based on this discussion and the FDA’s feedback, the company now expects to resubmit its BLA before the end of calendar year 2025. These details were disclosed through a press release dated September 29, 2025 that is filed as an exhibit.